CAMP4 THERAPEUTICS CORPORATION
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics C… Read more
CAMP4 THERAPEUTICS CORPORATION (CAMP) - Net Assets
Latest net assets as of December 2025: $47.70 Million USD
Based on the latest financial reports, CAMP4 THERAPEUTICS CORPORATION (CAMP) has net assets worth $47.70 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($117.81 Million) and total liabilities ($70.10 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $47.70 Million |
| % of Total Assets | 40.49% |
| Annual Growth Rate | 9.42% |
| 5-Year Change | -40.5% |
| 10-Year Change | -70.91% |
| Growth Volatility | 77.97 |
CAMP4 THERAPEUTICS CORPORATION - Net Assets Trend (1985–2025)
This chart illustrates how CAMP4 THERAPEUTICS CORPORATION's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CAMP4 THERAPEUTICS CORPORATION (1985–2025)
The table below shows the annual net assets of CAMP4 THERAPEUTICS CORPORATION from 1985 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $47.70 Million | -24.45% |
| 2024-12-31 | $63.14 Million | +151.03% |
| 2023-12-31 | $-123.73 Million | -59.59% |
| 2022-12-31 | $-77.53 Million | -196.69% |
| 2021-12-31 | $80.18 Million | -19.27% |
| 2020-12-31 | $99.32 Million | -27.99% |
| 2019-12-31 | $137.92 Million | -32.94% |
| 2018-12-31 | $205.65 Million | +3.39% |
| 2017-12-31 | $198.92 Million | +21.29% |
| 2016-12-31 | $164.00 Million | -13.43% |
| 2015-12-31 | $189.45 Million | +25.14% |
| 2014-12-31 | $151.38 Million | +13.70% |
| 2013-12-31 | $133.15 Million | +13.27% |
| 2012-12-31 | $117.55 Million | +370.63% |
| 2011-12-31 | $24.98 Million | +41.90% |
| 2010-12-31 | $17.60 Million | -8.32% |
| 2009-12-31 | $19.20 Million | -17.24% |
| 2008-12-31 | $23.20 Million | -68.40% |
| 2007-12-31 | $73.42 Million | -51.46% |
| 2006-12-31 | $151.25 Million | -14.12% |
| 2005-12-31 | $176.11 Million | +11.26% |
| 2004-12-31 | $158.29 Million | +142.17% |
| 2003-12-31 | $65.36 Million | +11.50% |
| 2002-12-31 | $58.62 Million | +56.00% |
| 2001-12-31 | $37.58 Million | +24.11% |
| 2000-12-31 | $30.28 Million | +7.78% |
| 1999-12-31 | $28.09 Million | +39.08% |
| 1998-12-31 | $20.20 Million | -6.91% |
| 1997-12-31 | $21.70 Million | -9.96% |
| 1996-12-31 | $24.10 Million | +5.24% |
| 1995-12-31 | $22.90 Million | +53.69% |
| 1994-12-31 | $14.90 Million | +22.13% |
| 1993-12-31 | $12.20 Million | +67.12% |
| 1992-12-31 | $7.30 Million | +97.30% |
| 1991-12-31 | $3.70 Million | +85.00% |
| 1990-12-31 | $2.00 Million | 0.00% |
| 1989-12-31 | $2.00 Million | +11.11% |
| 1988-12-31 | $1.80 Million | -18.18% |
| 1987-12-31 | $2.20 Million | +29.41% |
| 1986-12-31 | $1.70 Million | +30.77% |
| 1985-12-31 | $1.30 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CAMP4 THERAPEUTICS CORPORATION's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28845600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | 0.01% |
| Other Components | $339.85 Million | 712.42% |
| Total Equity | $47.70 Million | 100.00% |
CAMP4 THERAPEUTICS CORPORATION Competitors by Market Cap
The table below lists competitors of CAMP4 THERAPEUTICS CORPORATION ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Benchmark Metals Inc
V:CEI
|
$143.60 Million |
|
Elicio Therapeutics Inc.
NASDAQ:ELTX
|
$143.62 Million |
|
Diamyd Medical AB (publ)
ST:DMYD-B
|
$143.63 Million |
|
PROTALIX BIOTHERAP.DL-01
F:PBDA
|
$143.64 Million |
|
Jiangsu Teeyer Intelligent Equipment Co.,Ltd.
SHG:603273
|
$143.54 Million |
|
Ginebra San Miguel Inc
PINK:GBSMF
|
$143.53 Million |
|
DOUGLAS ELLIMAN DL-01
F:8OT
|
$143.47 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
$143.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CAMP4 THERAPEUTICS CORPORATION's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 63,144,000 to 47,704,000, a change of -15,440,000 (-24.5%).
- Net loss of 80,403,000 reduced equity.
- Other factors increased equity by 64,963,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-80.40 Million | -168.55% |
| Other Changes | $64.96 Million | +136.18% |
| Total Change | $- | -24.45% |
Book Value vs Market Value Analysis
This analysis compares CAMP4 THERAPEUTICS CORPORATION's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.53x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 29.32x to 3.53x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $0.19 | $5.55 | x |
| 1986-12-31 | $0.25 | $5.55 | x |
| 1987-12-31 | $0.29 | $5.55 | x |
| 1988-12-31 | $0.24 | $5.55 | x |
| 1989-12-31 | $0.30 | $5.55 | x |
| 1990-12-31 | $0.24 | $5.55 | x |
| 1991-12-31 | $0.37 | $5.55 | x |
| 1992-12-31 | $0.71 | $5.55 | x |
| 1993-12-31 | $1.07 | $5.55 | x |
| 1994-12-31 | $1.31 | $5.55 | x |
| 1995-12-31 | $1.88 | $5.55 | x |
| 1996-12-31 | $2.01 | $5.55 | x |
| 1997-12-31 | $1.82 | $5.55 | x |
| 1998-12-31 | $1.71 | $5.55 | x |
| 1999-12-31 | $2.30 | $5.55 | x |
| 2000-12-31 | $2.08 | $5.55 | x |
| 2001-12-31 | $2.69 | $5.55 | x |
| 2002-12-31 | $3.94 | $5.55 | x |
| 2003-12-31 | $4.25 | $5.55 | x |
| 2004-12-31 | $7.06 | $5.55 | x |
| 2005-12-31 | $7.52 | $5.55 | x |
| 2006-12-31 | $6.48 | $5.55 | x |
| 2007-12-31 | $3.07 | $5.55 | x |
| 2008-12-31 | $0.94 | $5.55 | x |
| 2009-12-31 | $0.76 | $5.55 | x |
| 2010-12-31 | $0.65 | $5.55 | x |
| 2011-12-31 | $0.88 | $5.55 | x |
| 2012-12-31 | $3.92 | $5.55 | x |
| 2013-12-31 | $3.70 | $5.55 | x |
| 2014-12-31 | $4.14 | $5.55 | x |
| 2015-12-31 | $5.13 | $5.55 | x |
| 2016-12-31 | $4.57 | $5.55 | x |
| 2017-12-31 | $5.50 | $5.55 | x |
| 2018-12-31 | $5.83 | $5.55 | x |
| 2019-12-31 | $4.10 | $5.55 | x |
| 2020-12-31 | $2.89 | $5.55 | x |
| 2021-12-31 | $2.27 | $5.55 | x |
| 2022-12-31 | $-2.15 | $5.55 | x |
| 2023-12-31 | $-10.20 | $5.55 | x |
| 2024-12-31 | $3.24 | $5.55 | x |
| 2025-12-31 | $1.57 | $5.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CAMP4 THERAPEUTICS CORPORATION utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -168.55%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2298.54%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 2.47x
- Recent ROE (-168.55%) is below the historical average (-24.47%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | -438.46% | -39.04% | 1.45x | 7.77x | $-5.83 Million |
| 1986 | 11.76% | 2.60% | 1.08x | 4.18x | $30.00K |
| 1987 | 4.55% | 1.33% | 0.99x | 3.45x | $-120.00K |
| 1988 | -50.00% | -9.89% | 1.98x | 2.56x | $-1.08 Million |
| 1989 | 10.00% | 1.83% | 1.85x | 2.95x | $0.00 |
| 1990 | -25.00% | -3.50% | 2.98x | 2.40x | $-700.00K |
| 1991 | 43.24% | 7.77% | 2.26x | 2.46x | $1.23 Million |
| 1992 | 42.47% | 8.66% | 2.24x | 2.19x | $2.37 Million |
| 1993 | 13.11% | 3.93% | 2.08x | 1.61x | $380.00K |
| 1994 | 16.78% | 5.47% | 2.07x | 1.48x | $1.01 Million |
| 1995 | 21.83% | 8.12% | 1.89x | 1.42x | $2.71 Million |
| 1996 | 2.49% | 1.22% | 1.67x | 1.22x | $-1.81 Million |
| 1997 | -12.62% | -5.76% | 1.69x | 1.30x | $-4.84 Million |
| 1998 | -6.97% | -3.77% | 1.45x | 1.27x | $-3.41 Million |
| 1999 | -5.02% | -1.63% | 1.54x | 2.00x | $-4.17 Million |
| 2000 | 17.58% | 4.17% | 2.51x | 1.68x | $2.25 Million |
| 2001 | 11.88% | 4.43% | 1.78x | 1.51x | $706.00K |
| 2002 | 8.80% | 5.16% | 1.12x | 1.53x | $-702.30K |
| 2003 | 8.74% | 4.44% | 1.32x | 1.49x | $-822.30K |
| 2004 | 5.10% | 3.67% | 1.12x | 1.24x | $-7.75 Million |
| 2005 | 8.27% | 6.70% | 1.06x | 1.16x | $-3.05 Million |
| 2006 | -20.62% | -14.03% | 0.97x | 1.52x | $-46.31 Million |
| 2007 | -114.61% | -59.72% | 0.99x | 1.95x | $-91.49 Million |
| 2008 | -214.08% | -50.49% | 1.41x | 3.00x | $-51.98 Million |
| 2009 | -56.52% | -9.68% | 1.97x | 2.97x | $-12.77 Million |
| 2010 | -18.65% | -2.87% | 2.06x | 3.15x | $-5.04 Million |
| 2011 | 20.89% | 3.76% | 2.69x | 2.06x | $2.72 Million |
| 2012 | 37.96% | 24.71% | 1.20x | 1.28x | $32.87 Million |
| 2013 | 8.86% | 5.00% | 1.32x | 1.35x | $-1.51 Million |
| 2014 | 10.90% | 6.59% | 1.24x | 1.34x | $1.37 Million |
| 2015 | 8.94% | 6.03% | 0.73x | 2.03x | $-2.00 Million |
| 2016 | -4.36% | -2.04% | 0.86x | 2.49x | $-23.55 Million |
| 2017 | 8.35% | 4.54% | 0.77x | 2.38x | $-3.27 Million |
| 2018 | 8.95% | 5.06% | 0.60x | 2.94x | $-2.17 Million |
| 2019 | -57.12% | -21.52% | 0.74x | 3.59x | $-92.57 Million |
| 2020 | -21.30% | -6.86% | 0.70x | 4.45x | $-31.09 Million |
| 2021 | -38.85% | -10.53% | 0.74x | 5.02x | $-39.17 Million |
| 2022 | 0.00% | -14.98% | 2.88x | 0.00x | $-36.44 Million |
| 2023 | 0.00% | -14083.14% | 0.01x | 0.00x | $-36.92 Million |
| 2024 | -82.02% | -7943.40% | 0.01x | 1.24x | $-58.11 Million |
| 2025 | -168.55% | -2298.54% | 0.03x | 2.47x | $-85.17 Million |
Industry Comparison
This section compares CAMP4 THERAPEUTICS CORPORATION's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CAMP4 THERAPEUTICS CORPORATION (CAMP) | $47.70 Million | -438.46% | 1.47x | $143.59 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |